Potent inhibition of platelet aggregation during percutaneous coronary intervention (PCI) using intravenous antagonists of the platelet glycoprotein (GP) IIb/IIIa receptor results in a significant and sustained reduction in the occurrence of...
Potent inhibition of platelet aggregation during percutaneous coronary intervention (PCI) using intravenous antagonists of the platelet glycoprotein (GP) IIb/IIIa receptor results in a significant and sustained reduction in the occurrence of...
Potent inhibition of platelet...